Twist Bioscience (NASDAQ:TWST) Stock: Insider Paula Green Sells 1,007 Shares

Posted by Geri Gentry on Nov 7th, 2026

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) SVP Paula Green sold 1,007 shares of the business’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $136,347.80. Following the completion of the sale, the senior vice president owned 105,625 shares of the company’s stock, valued at $14,301,625. This trade represents a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paula Green also recently made the following trade(s):

On Friday, October 2nd, Paula Green sold 10,088 shares of Twist Bioscience stock. The stock was sold at an average price of $188.88, for a total transaction of $1,905,421.44.
On Monday, September 21st, Paula Green sold 294 shares of Twist Bioscience stock. The shares were sold at an average price of $165.49, for a total value of $48,654.06.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $120.79 on Friday. The business’s 50 day simple moving average is $151.35 and its 200 day simple moving average is $91.08. The stock has a market capitalization of $7.57 billion, a PE ratio of -54.41 and a beta of 2.25. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $219.71. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TWST shares. BWS Financial reissued a “sell” rating and set a $45.00 price target on shares of Twist Bioscience in a research report on Friday, September 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, September 21st. Robert W. Baird lifted their target price on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Leerink Partners lifted their target price on shares of Twist Bioscience from $160.00 to $190.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. Finally, Piper Sandler lifted their price target on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $153.00.

View Our Latest Stock Analysis on TWST

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently modified their holdings of the company. Abacus Wealth Partners LLC lifted its stake in Twist Bioscience by 4.3% in the third quarter. Abacus Wealth Partners LLC now owns 2,332 shares of the company’s stock valued at $451,000 after buying an additional 96 shares during the last quarter. Root Financial Partners LLC bought a new stake in Twist Bioscience in the 3rd quarter valued at about $33,000. GAMMA Investing LLC lifted its holdings in Twist Bioscience by 24.4% in the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock worth $97,000 after buying an additional 185 shares during the period. Abel Hall LLC increased its holdings in Twist Bioscience by 3.6% during the third quarter. Abel Hall LLC now owns 5,514 shares of the company’s stock valued at $1,066,000 after buying an additional 191 shares during the last quarter. Finally, Allworth Financial LP grew its position in shares of Twist Bioscience by 54.9% during the 2nd quarter. Allworth Financial LP now owns 601 shares of the company’s stock worth $62,000 after buying an additional 213 shares in the last quarter.

More Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

Positive Sentiment: Twist launched MRD Express, potentially expanding its presence in minimal residual disease testing. Investors may look for further details on the product and business outlook around earnings. Article: Twist Bioscience stock enters earnings week after MRD Express launch
Neutral Sentiment: CEO Emily Leproust and three other insiders sold a combined 6,677 shares at $135.40. The sales were disclosed as covering tax withholding on equity-award vesting, and each seller retained a substantial stake.
Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The provided article headline does not specify the report’s allegations, but its release appears to have hurt sentiment. Article: Twist Bioscience falls amid negative report

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.